Assessment of Pain Relief and Mobility Improvement: A Randomized Clinical Trial Comparing Commiphora myrrha and Etoricoxib in Osteoarthritis Patients

Abstract

Osteoarthritis pain refers to the discomfort and aching experienced in the joints, often accompanied by stiffness, swelling, and reduced range of motion. NSAIDs are the most commonly prescribed medicines for the management of arthritisinduced pain. Prolonged NSAID use can lead to several health issues, such as gastric ulcers, hypertension, and cardiovascular risks, and also significantly impact their quality of life. So, patients on chronic NSAID therapy require careful monitoring and alternative treatment options. The purpose of the present study was to compare the safety and efficacy of Commiphora myrrha versus Etoricoxib in patients with osteoarthritis pain. In this, a 30-day randomised, parallel-group trial was conducted among 102 osteoarthritis patients aged between 40 and 75 who were treated with either Commiphora myrrha (100 mg, twice daily) or Etoricoxib (90 mg, once daily). Outcomes were assessed using WOMAC scores (pain, stiffness, function), VAS pain scale, PGA for pain, and 6MWT to evaluate mobility. Adverse medication events were recorded for assessing the safety of both. When compared to the Etoricoxib group, the Commiphora myrrha was safer and exhibited a long-term improvement in mobility and pain reduction than Etoricoxib. In conclusion, Commiphora myrrha showed as an effective alternative to Etoricoxib for managing osteoarthritis pain and improving functional mobility.